Click here to visit Company website
Hybrigenics SA, a biotechnology and pharmaceutical company, engages in the research and development of programs focused on targets and therapies for the treatment of cancer. Its development program is based on Inecalcitol, a phase II synthetic chemical derivative of calcitriol, the naturally active form of vitamin D, for the treatment of hormone-refractory prostate cancer.